DK1091745T3 - Behandling af hyperproliferative forstyrrelser - Google Patents

Behandling af hyperproliferative forstyrrelser

Info

Publication number
DK1091745T3
DK1091745T3 DK99930790T DK99930790T DK1091745T3 DK 1091745 T3 DK1091745 T3 DK 1091745T3 DK 99930790 T DK99930790 T DK 99930790T DK 99930790 T DK99930790 T DK 99930790T DK 1091745 T3 DK1091745 T3 DK 1091745T3
Authority
DK
Denmark
Prior art keywords
inhibitor
ceramide
treatment
preferred
inhibitors
Prior art date
Application number
DK99930790T
Other languages
English (en)
Inventor
Barry James Maurer
C Patrick Reynolds
Myles Cabot
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of DK1091745T3 publication Critical patent/DK1091745T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99930790T 1998-06-29 1999-06-28 Behandling af hyperproliferative forstyrrelser DK1091745T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9113898P 1998-06-29 1998-06-29
PCT/US1999/014591 WO2000000207A1 (en) 1998-06-29 1999-06-28 Treatment of hyperproliferative disorders

Publications (1)

Publication Number Publication Date
DK1091745T3 true DK1091745T3 (da) 2008-12-15

Family

ID=22226266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99930790T DK1091745T3 (da) 1998-06-29 1999-06-28 Behandling af hyperproliferative forstyrrelser

Country Status (12)

Country Link
US (1) US6352844B1 (da)
EP (1) EP1091745B1 (da)
JP (1) JP4965764B2 (da)
CN (1) CN100358529C (da)
AT (1) ATE409486T1 (da)
AU (1) AU4724599A (da)
BR (1) BR9912501A (da)
CA (1) CA2335941C (da)
DE (1) DE69939651D1 (da)
DK (1) DK1091745T3 (da)
ES (1) ES2316188T3 (da)
WO (1) WO2000000207A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
GB0006539D0 (en) * 2000-03-17 2000-05-10 Oxford Glycosciences Uk Ltd Therapies
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
EP1195604A1 (en) * 2000-09-29 2002-04-10 Warner-Lambert Company Methods and compositions for screening modulators of lipid kinases
JP4384409B2 (ja) * 2000-12-05 2009-12-16 チルドレンズ・ホスピタル・ロス・アンジエルス バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
US20030226181P1 (en) * 2002-05-31 2003-12-04 Mason Harleigh C. Apple tree named 'Rosy Glow'
JP3405981B1 (ja) * 2002-06-26 2003-05-12 日本財経株式会社 酢酸セルロースの製造方法
JP4469720B2 (ja) * 2002-09-20 2010-05-26 メディシン テクノロジーズ インコーポレーテッド 治療薬及び対応する治療
JP2006518384A (ja) * 2003-01-31 2006-08-10 チルドレンズ・ホスピタル・ロス・アンジエルス 改善されたバイオアベイラビリティを有するフェンレチニドの経口組成物、およびその使用方法
MXPA05008860A (es) * 2003-02-21 2005-10-05 Los Angeles Childrens Hospital Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.
US20050101674A1 (en) * 2003-11-12 2005-05-12 Maurer Barry J. PPMP as a ceramide catabolism inhibitor for cancer treatment
US20070258970A1 (en) * 2003-12-09 2007-11-08 Robert Blumenthal Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
ES2459750T3 (es) 2004-03-02 2014-05-12 Mcgill University Composiciones y métodos para prevenir o tratar una respuesta inflamatoria
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US7652029B2 (en) * 2004-07-09 2010-01-26 Medisyn Technologies, Inc. Therapeutic compound and treatments
WO2006078336A2 (en) * 2004-10-28 2006-07-27 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20060257493A1 (en) * 2005-04-28 2006-11-16 Amiji Mansoor M Nanoparticulate delivery systems for treating multi-drug resistance
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
WO2007115134A2 (en) 2006-03-29 2007-10-11 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
AU2007329759B2 (en) 2006-10-27 2013-05-30 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
CN101687031B (zh) * 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
US20100311765A1 (en) * 2007-09-28 2010-12-09 Barry James Maurer Metabolic degradation inhibitors for anti-hyperproliferative agents
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
US8088822B2 (en) * 2008-07-08 2012-01-03 Ji Zhang Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
CN101623277B (zh) * 2008-07-08 2014-07-16 上海交通大学医学院附属瑞金医院 芬维a胺及其活性衍生物的新用途及其药物组合物
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2011060332A2 (en) 2009-11-12 2011-05-19 Texas Tech University Compositions and methods for treating hyperproliferative disorders
US8450350B2 (en) * 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
CA2817957C (en) * 2010-11-15 2016-05-10 Texas Tech University Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
EP0671953A4 (en) 1992-11-13 1996-01-10 Univ Ohio State Res Found ANALOGS OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE ARYLAMIDE.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5464870A (en) * 1993-02-10 1995-11-07 Ortho Pharmaceutical Corporation Methods of inhibiting development of leukoplakia with fenretinide
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US5635536A (en) 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
JPH09176083A (ja) 1995-12-28 1997-07-08 Sankyo Co Ltd 新規化合物ｆ−１２５０９ａ
US5821072A (en) 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
US5885786A (en) 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance

Also Published As

Publication number Publication date
JP2002519329A (ja) 2002-07-02
AU4724599A (en) 2000-01-17
ATE409486T1 (de) 2008-10-15
WO2000000207A9 (en) 2000-05-18
WO2000000207A1 (en) 2000-01-06
JP4965764B2 (ja) 2012-07-04
ES2316188T3 (es) 2009-04-01
CN1308538A (zh) 2001-08-15
US6352844B1 (en) 2002-03-05
BR9912501A (pt) 2001-05-02
EP1091745A1 (en) 2001-04-18
CA2335941C (en) 2011-03-22
EP1091745B1 (en) 2008-10-01
EP1091745A4 (en) 2003-08-27
CN100358529C (zh) 2008-01-02
CA2335941A1 (en) 2000-01-06
DE69939651D1 (de) 2008-11-13

Similar Documents

Publication Publication Date Title
DK1091745T3 (da) Behandling af hyperproliferative forstyrrelser
PT840601E (pt) Thip para o tratamento de desordens do sono
BR0008958A (pt) Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
BRPI0408784A (pt) método para usar um composto
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
PT1274685E (pt) Derivado de piridina-n-oxido e processo para a sua transformacao em compostos farmaceuticamente eficazes
EA199800866A1 (ru) Способ снятия боли
FI953002A (fi) Menetelmä kroonisen eturauhastulehduksen hoitamiseksi 17beta-N-monosubstituoiduilla karbamoyyli-4-atsa-5alfa-androst-1-en-3-oneilla
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
BR9911150A (pt) Método de tratamento
BR0012318A (pt) Compostos semelhantes a amino ceramida e métodos terapêuticos de uso
BR9915899A (pt) Composto, composição farmacêutica e método para tratar ou inibir distúrbios associados com contração do músculo liso.
DK1011672T3 (da) Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger
MEP20308A (en) THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren